| Code | CSB-RA836195MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ulenistamab, targeting ZG16B (zymogen granule protein 16B). ZG16B is a secreted lectin predominantly expressed in the pancreas and gastrointestinal tract, where it functions as part of the innate immune defense system by binding to bacterial peptidoglycans and facilitating their aggregation and clearance. This protein plays a critical role in maintaining gut homeostasis and protecting the intestinal mucosa from bacterial invasion. Altered expression of ZG16B has been associated with inflammatory bowel disease, pancreatic disorders, and colorectal cancer, making it a valuable target for investigating digestive system pathologies and host-microbiome interactions.
Ulenistamab represents a therapeutic antibody designed to modulate ZG16B activity, though clinical development details remain limited. This biosimilar antibody provides researchers with a valuable tool for exploring ZG16B-mediated mechanisms in gastrointestinal immunity, pancreatic function, and microbial defense pathways. It enables investigation of ZG16B's role in disease pathogenesis and supports studies examining therapeutic intervention strategies in inflammatory and neoplastic conditions of the digestive system.
There are currently no reviews for this product.